Compare Enveric Biosciences Inc (ENVB) vs Mondaycom Ltd (MNDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Mondaycom Ltd — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Mondaycom Ltd trades at $88.99 (market cap $3.53B). The key difference: Mondaycom Ltd is far larger — about 527.7× Enveric Biosciences Inc's market cap, and Mondaycom Ltd is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Mondaycom Ltd for 16 Days on average.
| ENVB | MNDY | |
|---|---|---|
Market Cap | $6.69M | $3.53B |
Volume | 41,141 | 583,371 |
Sector | Health | Technology |
52-Week High | $10.80 | $205.24 |
52-Week Low | $1.27 | $58.81 |
Typical Hold Time | 14 Days | 16 Days |
Enterprise Value | -$1.60M | $2.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Monday.com (MNDY) trades at $83.51, down 0.93% on the day, with a bearish technical signal and neutral oscillators. The stock shows strong fundamentals with revenue growth from $1.2B in 2025 to $1.4B in 2026 and consistent earnings beats. Recent news highlights its inclusion in growth stock lists and an upcoming AI-focused conference, Elevate '26.
The outlook is positive given analyst consensus of $110.42 price target and 65% buy ratings, but risks include competitive pressure from Meta's enterprise push and volatile cash flow trends. Investment appeal hinges on execution of AI initiatives and high-value client growth against premium valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →
